recombinant human growth hormone

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Abdominal Obesity

Conditions

Abdominal Obesity, Metabolic Syndrome, Obesity

Trial Timeline

Jan 1, 1999 → May 1, 2005

NCT ID

NCT00781547

About recombinant human growth hormone

recombinant human growth hormone is a phase 3 stage product being developed by Pfizer for Abdominal Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00781547. Target conditions include Abdominal Obesity, Metabolic Syndrome, Obesity.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00781547	Phase 3	Completed	Jan 1, 1999	May 1, 2005	Abdominal Obesity

Competing Products

20 competing products in Abdominal Obesity

See all competitors

Product	Company	Stage	Hype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tablets	Jiangsu Hengrui Medicine	Phase 3	77
HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	77
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	65
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	77
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
ACZ885 + Placebo	Novartis	Phase 2	52
Evolocumab + Placebo	Amgen	Phase 1	32
tigecycline	Pfizer	Phase 3	76
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin	Pfizer	Approved	84
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	76

Other Products from Pfizer